Also trades as: 0HOJ.L (LSE) · $vol 0M
BPMC NASDAQ
Blueprint Medicines Corporation
1W: +0.1%
1M: +1.0%
3M: +57.7%
1Y: +7.4%
3Y: +133.7%
5Y: +68.9%
$129.46
Last traded 2025-07-18 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships0
As Filer
counterparties named
2
As Counterparty
mentioned by others
2021-11-09
Earliest Filing
2024-02-22
Latest Filing
Mentioned As Counterparty
2 mentionsOther companies that named BPMC in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| RIGL RIGEL PHARMACEUTICALS INC | target | Rigel Pharmaceuticals acquired U.S. rights to pralsetinib from Blueprint Medicines Corporation. | 2024-02-22 | View |
| ZLAB Zai Lab Ltd | partner | License and collaboration agreement for development and commercialization of BLU-701 and BLU-945 in China, Macau, Hong K | 2021-11-09 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR